加巴喷丁预防带状疱疹后神经痛的疗效:随机对照临床试验的研究方案
本方案拟招募≥50岁、VAS疼痛评分≥4分的带状疱疹患者134例,随机接受加巴喷丁(最大1800 mg/日,共5周)或安慰剂,两组均用伐昔洛韦1000 mg每日三次共7天及必要时镇痛药。主要结局为皮疹出现后12周VAS评分为0的患者百分比,次要结局包括生活质量、睡眠障碍及神经病理性疼痛百分比。
要点
- 研究对象为≥50岁、VAS评分≥4分的带状疱疹患者。
- 加巴喷丁最大1800 mg/日用5周,对照为安慰剂。
- 主要结局为皮疹出现后12周VAS评分为0的患者百分比。
核心结论
- 加巴喷丁是一种抗惊厥类镇痛药,可能通过其在背角神经元的抗超敏作用预防带状疱疹后神经痛的发生。
研究设计与样本
- 随机对照临床试验方案,计划从全科医生诊所招募134例≥50岁、VAS疼痛评分≥4分的带状疱疹患者。
- 参与者随机接受加巴喷丁(最大1800 mg/日)或安慰剂,共5周。
- 两组均接受伐昔洛韦1000 mg片剂每日三次共7天(症状出现72小时内开始)及必要时镇痛药。
主要发现
- 主要结局为皮疹出现后12周VAS疼痛评分为0的患者百分比。
- 次要结局包括SF-12问卷测量的生活质量变化、医学结局研究睡眠量表测量的睡眠障碍变化,以及Douleur Neuropathique in 4 Questions测量的神经病理性疼痛患者百分比。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postherpetic neuralgia (PHN) is a chronic neuropathic pain that results from alterations of the peripheral nervous system in areas affected by the herpes zoster virus. The symptoms include pain, paresthesia, dysesthesia, hyperalgesia, and allodynia. Despite the availability of pharmacological treatments to control these symptoms, no treatments are available to control the underlying pathophysiology responsible for this disabling condition. METHODS/DESIGN: Patients with herpes zoster who are at least 50 years old and have a pain score of 4 or higher on a visual analogue scale (VAS) will be recruited. The aim is to recruit 134 patients from the practices of general physicians. Participants will be randomized to receive gabapentin to a maximum of 1800 mg/day for 5 weeks or placebo. Both arms will receive 1000-mg caplets of valacyclovir three times daily for 7 days (initiated within 72 h of the onset of symptoms) and analgesics as needed. The primary outcome measure is the percentage of patients with a VAS pain score of 0 at 12 weeks from rash onset. The secondary outcomes measures are changes in quality of life (measured by the SF-12 questionnaire), sleep disturbance (measured by the Medical Outcomes Study Sleep Scale), and percentage of patients with neuropathic pain (measured by the Douleur Neuropathique in 4 Questions). DISCUSSION: Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons. TRIAL REGISTRATION: ISRCTN Registry identifier: ISRCTN79871784 . Registered on 2 May 2013.
引用
- Rullán M, Bulilete O, Leiva A, et al. Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. Trials. 2017. PMID: 28088231. doi:10.1186/s13063-016-1729-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。